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The paired helical filament (PHF), which comprises the major tibrous clement of the neurofibrillary tan@ of Aleheimcr’s disease, is composed 
of abnormally phosphorylated microtubule-associated protein tau. Hcrc we show that p42 MAP kinasc phosphorylatcs recombinant tau and 
converts it to a form which is similar to PHF tau. Of the major scrinelthrconinc protein phosphatases found in mammalian tissues only protein 
phosphatase 2A (PP2A) could dephosphutylatc tau phosphorylated in this manner, with PP2A, being the most effective form of the enrymc. 
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1, INTRODUCTION 
Abundant senile plaques and neurofibrillary tangles 
constitute the major pathological characteristics of Alz- 
heimer’s disease. Neurofibrillary tangles appear within 
the vast majority of nerve cells that degenerate during 
the course of the disease, where their presence is indica- 
tive of dementia (reviewed in [I]). Paired helical fila- 
ments (PHFs), which are composed of the microtubule- 
associated protein tau, form the principal fibrous com- 
ponent of the neurofibrillary tangle [2-4]. In human 
adult brain, tau comprises ix isoforms of 48-67 kDa 
apparent molecular mass [5], while tau isolated from 
Alzheimer PHFs runs as three bands of 60, 64 and 68 
kDa apparent molecular mass [2,6]. After dephosphor- 
ylation with alkaline phosphatasc these bands align 
with the six rau isoforms expressed in E. cofi, indicating 
that PHF tau consists of all six isoforms in an abnor- 
mally phosphorylatcd state [7]. Abnormal phosphoryla- 
tion probably produces a change in tau that favours 
self-association over microtubule binding, resulting in 
the formation of PHFs. 
Several sites that are abnormally phosphorylated in 
PHF tau have been identified through the use of phos- 
phorylation-dependent antibodies which recognize 
PHF tau but do not recognize normal adult brain tau. 
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Thus, antiserum T3P recognizes phosphoserine-396 [2] 
and antibody AT8 recognizes phosphoserine-I99 an& 
or phosphoserine-202 [S] (using the numbering of the 
largest human brain tau isoform [S]). Each of these 
serines is followed by a proline, suggesting that protein 
kinases or protein phosphatases with specificity for 
phosphoseryi-proline may be involved. Recently, a pro- 
tein kinase with the characteristics of a mitogen-acti- 
vated protein (MAP) kinase was purified from pig brain 
and shown to phosphorylate recombinant r.u to en 
Alzheitner-like state, as evidenced by a reduction i;r gel 
mobility and the phosphorylation of serine/threonine- 
proline sites [9]. Moreover, two brain protein kinases 
(PK36 and PK40) phosphorylate tau at serine-396 and 
other serine/threonine-proline sites [IO] and a kinase 
called tau protein kinase I also phosphorylates tau at 
some scrine/threonine-proline sites [l I]. The relation- 
ships, if any, of these protein kinases to MAP kinase are 
not clear. Nothing is known about the protein phos- 
phatases that can dephosphorylate au phosphorylated 
at serine/threonine-proline sites. 
In this paper we show that activated recombinant p42 
MAP kinase (also known as ERKZ) phosphorylatcs 
recombinant tau, converting it to a form which is simi- 
lar to PHF tau, as judged by a reduction in gel mobility 
and the appearance of the T3P and AT8 epitopes. Tau 
phosphorylated in this manner could only be 
dephosphoryleted by a type 2A protein phosphatase 
(PPZA). This suggests that an increase in the activity of 
a MAP kinase or a defect 
underlie the abnormal state 
ease. 
in a PP2A enzyme could 
of tau in Alzheimer’s dis- 
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2. MATERIALS AND METHODS 
2. I. Mttrariuis 
The largest human brain tau isolbrm was expressed in E. co/i from 
cDNA clone htau40 and purified as described [12]; the tau concentra- 
tions were determined by amino acid analysis. Protein phosphatases 
2A, and 2Az partially purified from rat liver extracts by chromatogra- 
phy on Mono-Q ([I 31; Mr. P. Fcrrigno) and highly purified catalytic 
subunits of protein phosphatase 1 and protein phosphatasc 2A from 
rabbit skeletal muscle: ([14]: Dr. D. Scbelling) were isolated at Dundeu 
by the investigators indicated in parentheses. The specific 20 residue 
inhibitor of cyclic AMP-dependent protein kinase (PKI) was synihe- 
sized by Mr. F.B. Caudwell. Recombinant mouse ~42 MAP kinnse 
expressed in E. coli [IS] was provided by Ms. S. Leevers and Dr. C. 
Marshall (Chester Beatty Laboratories, Institute for Canccr Research, 
London) and activated at Dundee by incubation with MAP kinase 
kinase ([16], Ms. S. Nakielny) and MBATP ([15]; Mr. D. Stokoe). 
Recombinant inhibitor-2 expressed in E. co/i and okadaic acid were 
gifts from Dr. A. de Paoli-Roach (University of Indiana, Indianapolis, 
USA) and Dr. Y. Tsukitani (Fujisawa Pharmaceutical Co., Tokyo, 
Japan). Antiserum T3P [2] was a gift from Dr. V.M.-Y. Let (Univcr- 
sity of Pennsylvania, Philadelphia, USA) and antibody ATS [B] a gift 
from Dr. A. Van de Voorde (Innogenetics, Gent, Belgium). 
2.2. Assay OJ MAP kitme aclivity 
incubations (0.05 ml) were carried out at 30°C and comprised 25 
mM Tris-HCI, pH 7.0. 0.1 mM EGTA. 0.1 mM sodium orthovana- 
date, 2.5 yM PKI, 0.2 mM phenylmcthylsulphonyl fluoride, tau pro- 
tein (1 yM) or myelin basic protein (0.33 m&ml), activated ~42 MAP 
kinasc (I U/ml or 5 U/ml). 10 mM magnesium acetate and 2 mM 
[$‘P]ATP (approximately IOb cpm/nmol). Reactions wcrc initiated 
with ATP, aliquots removed after various times ranging from 5 min 
to 24 11 and used for SDS-PAGE. Alternatively, incorporation or 
l’P-radioactivity was mensured after adsorption to Whatman PSI 
paper. as described [17]. One unit of activity (U) was defined as the 
amount which catalysed the incorporation of I nmol of phosphate into 
myclin basic pro&in per min. Prior to the protein phosphatasc assays 
tau phosphorylated with I U/ml MAP kinase for 24 h was run over 
a Sephadex GSO superfine column (20 x 1 cm) in 50 mM Tris-HCI. pH 
7.4.0.5 M NaCI. 0. I% P-mercaptoethanol (v/v), 0.02% Brij 35 (w/v), 
in order to separate labelled 1au from [y-‘?P]ATP. The tau fractions 
were concentrated to approximately 30,000 cpm/lO ~1 and dialyzed 
extensively against 50 mM Tris-HCI, pH 7.4,O. I% P-mercaptocthanol 
(v/v), 0.02% Brij 35 (w/v). Precipitation with 20% TCA (w/v) indicated 
that all [r_“P]ATP had been removed. 
2.3. Assu~v of prorcirr phosphatuses 
“P-Labelled phosphorylase N (containing I .O IIIOI phosphate/mol 
subunit) was prepared as in [14] and “P-labelled tau (containing 7mol 
phosphate/mol) as in section 2.2, Protein phosphatase assays were 
carried out as described previously [14,18,19]. One unit of activity (U) 
was that amount which catalysed the release of I pmol of phosphate 
from “‘P-labelled substrate in I min. To assess ~he relative contribu- 
tions of PPI and PP2A to the dephosphorylation f phosphorylase 
and tau in brain extracts, assays were carried out in the absence and 
presence of 2 nM okadaic acid or 200 nM inhibitor-2 PP2B was 
assayed in an identical manner, except hat 0.1 mM EGTA WPS re- 
placed by 0. I mM CaCl?, while PPX was assayed in the presence of
10 mM MgCI,. 
3, RESULTS 
3.1. PI~osplzorykution j’ tarI by ~42 MAP kimse 
Tau protein incubated with p42 MAP kir?ese For 24 
h incorporated 6-8 n-101 phosphate per mol protein at 
1 U/ml MAP kinase and LO-12 mol phosphate per mol 
protein at 5 U/ml MAP kinase. A typical time-course of
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Fig. 1. Time-course of phosphorylation of recombinant human tau 
protein with p42 MAP kinase. One PM of the 441 amino acid brain 
isoform was pliosphorylated with I U/ml p42 MAP kinase, as de- 
scribed in Materials and Methods. Similar results were obtained in 
four separate xperiments. 
phosphorylation isshown in Fig. 1, High stoichiomctric 
ratios required long incubation times, with only l-2 mol 
phosphate per mot tau incorporated within 30 min. By 
SDS-PAGE phosphorylated tau showed a reduced gel 
mobility, running at 72 kDa apparent molecular mass 
after a 24 h incubation with MAP kinase instead of 67 
kDa when non-phosphorylated (Fig. 2); the apparent 
molecular mass increased throughout the incubation 
period and was most pronounced at late time-points 
(Fig. 2a-c). Phosphorylated tau became immunoreac- 
tive with the anti-PI-IF tau-specific antibodies T3P and 
AT& demonstrating phosphorylation of serine-396 and 
serines-199 and/or -202 (Fig. 2d,e). These residues only 
became phosphorylatcd following prolonged incuba- 
tion of tau with MAP kinase (Fig. 2d,e). Phosphoamino 
acid analysis of “‘P-labelled tau containing 7 mol phos- 
phate per mol protein revealed similar amounts of 
phosphoserine and phosphothreonine (Fig. 3). No 
phosphotyrosine was present. 
3.2. MentiJicutiorr of the major tclu phosphuse itt btnin 
cstracts 
Four major types of serine/threonine protein phos- 
phatase catalytic subunit have been identified in mam- 
malian tissues, termed protein phosphatases I, 2A, 2B 
and 2C (PPI, PP2A, PP2B and PP2C). PPt and PP2A 
are active in the absence of divalent cations, while PP2B 
and PP2C have absolute requirements for Ca” and 
Mg?‘, respectively (reviewed in [20]). In highly diluted 
extracts of brain and other tissues, it has been shown 
(using [“zP]-pllosphorylase as a substrate) that PPZA is 
inhibited almost completely by 2 nM okadaic acid, 
whereas PPI is unaffected at this concentration. Con- 
verse!y, PP! is in!?ibited a!_most co_mp!etely b 200 nM 
inhibitor-2, whereas PP2A is unaffected [21]. Table I 
shows that 2 nM okadaic acid and inhibitor-2 inhibited 
the dephosphorylation of phosphorylase by 56% and 
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Fig. 2. SDS-PAGE of recombinant human tau protein phosphorylated 
with p42 MAP kinase for various times. (a) Coomassic-stained gel; (b) 
Autoradiogram of (a); (c) lmmunoblot with the general anti-tau anti- 
serum 133; (d) Immunoblot with the anti-PHF fsu-specific antiserum. 
T3P; (e) Immunoblo~ with the anti-PHF tau-specific antibody AT& 
Lanes: (I) no MAP kinase; (2) 0.5 h; (3) I h; (4) 2 h; (5) 4 h; (6) 8 h; 
(7) I2 h; (8) IS h; (9) 24 h; (10) no MAP kinase. Note the increase in 
apparent molecular mass as a function of time and the appearance of
the T3P and AT8 cpitopes. Similar ~IW&S were obtained in three 
separate xperiments. 
41%, respectively. Thus, PPl contributed 43 f 2% and 
PP2A 57 1 2% of the phosphorylase phosphatase activ- 
ity in brain extracts, a similar result to that reported in 
[21]. In contrast, when the same extracts were assayed 
with 32P-labelled tau, 2 nM okadaic acid inhibited activ- 
ity by 98% and 200 nM inhibitor-2 by only 4%. Thus, 
Table 1 
Effect of okadaic acid, inhibitor-2 and divalent cations on the 
dephosphorylation f glycogcn phosphorylase and tau hy 1~81 brain 
CXlraJXS 
Additions to assay 
None 
Inhibitor-2 (0.2 ,uM) 
Okndaic acid (2 VW) 
Okadaic acid (10 nM) 
Okadaic acid (IO nM) + 
Mg’+ (10 mM) 
Okadaic acid (IO nM) + 
Ca” (0.1 mM) 
PhP activity (%) TP activity (8) 
I00 100 
59 96 
44 2 
ND I 
ND I 
ND 4 
Rat brain was homogcnised in 3 vols. of buffer/g wet weight as de- 
scribed [39], except for inclusion ofa protcinase inhibitorcoektail[4!& 
and the homogenates centrifuged for I5 min at 16,OQO xg (prepared 
by Mr. P. Ferrigno). The supernatant was decanted and assayed (rt a 
300.fold final dilution (5 mgIml) using IO PM [3zP]l)hosphorylasc or 
I.5 yM [j?P]tau as subitratcs. The 100% value corresponds PO 12 
mu/ml phosphorylasc phosphatasc (PhP) and 0.3 mu/ml tau phos- 
phstase (TP) in the undiluted brain extract. Diluted extracts and 
inhibitor-Z were preincubated for 15 min prior to iniliadng the reac- 
tion with substrate, in order to achieve maximal inhibition of PPI. 
Similar results were obtained with two direrent brain cxtmcls and two 
preparations of [‘?]tau substrate. ND = not determined. 
in the absence of divalent cations, forms of PP2A ac- 
counted for virtually all the tau phosphatase activity, 
the contribution of PPl being negligible. 
PP2B is only affected by okadaic acid at concentra- 
tions above 500 nM, while PP2C is resistant 1221. The 
contributions of PPZB and PP2C to the tau phosphatase 
activity in brain extracts were therefore assessed in the 
presence of 10 nM okadaic acid (to inhibit PP2A) and 
either 0.1 mM Ca”’ or 10 mM Mg”‘. As shown in Table 
I, tau phosphatase activity was negligible in either the 
presence or absence of Ca” or Mg”, indicating that 
neither PP2B nor PP2C are significant au phosphat- 
ase5. 
The PP2A catalytic subunit (termed PP2Ac) does not 
exist as such in vivo, but is complexed to a 60 kDa 
A-subunit, which in turn can be complexed to other 
subunits, termed B, B’ and B” (reviewed in [20]). The 
hcterodimeric species consisting of PP2Ac complexcd to 
the A-subunit is termed PP2A2 and a major trimeric 
species comprising PP2Ac, the A-subunit and a 55 kDa 
B-subunit is termed FP2Al. PP2& the A-subunit and 
the a-isoform of the B-subunit are found in a variety of 
mammalian tissues, the highest levels of mRNA being 
found in brain, although an additional ,&isoform of the 
B-subunit specific to the nervous system has also been 
identified [23-261. The tau phosphatasc:phosphorylase 
phosphatase activity ratios of different forms of PP2A 
are summarized in Table 11. PP2A, has a 7-S-fold 
higher atio than PP2A-,, and a 40-fold higbcr ratio than 
PP2Ac. The activity ratio in brain extracts is similar to 
that of PP2A,. The free catalytic subunit of PPI had 
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Table I1 
Different forms of protein phosphatase 3A have distinct au phosphat- 
ase (TP):phosphorylase phosphstasc (PhP) activity ratios 
Form of PP2A TPiPhP ratio 
Brain extract 0.36 
PP2A, 0.48 
PP2A> 0.062 
PP3Ac 0.011 
PPlc 0.002 
Brain extracts were assayed at a 300~fold final dilution in the presence 
of 200 nM inhibitor-2 to inactivate PPI. Assays were carried act at 
1OyM phosphorylase or1.5 k[rM [lzP]tau. Similar resirlts were obtained 
in sepamte xperiments with two different preparations of tau and 
phosphorylase and two different brain extracts. 
negligible tau phosphatase activity (Table II), in agree- 
ment with the results obtained in brain extracts (Table 
I). 
Incubation of 3’P-labelled tau at 30°C with concen- 
trations of PPZA, two-fold higher than those employed 
in the standard (10 min) assay re!eased almost 40% of 
the [3’P]phosphate after 1 h and 45% after 2 h. The 
proportion of phosphoserine and phosphothreonine in
tau that had been incubated for 1 h or 2 h with PP2A, 
was similar to that of tau which had not been treated 
with PP2A (Fig. 3), indicating that both threonine and 
serine residues in tau are dephosphorylated by PPI?A, 
(Fig. 3). 
4. DISCUSSIQN 
MAP kinases are a group of serinejthreonine kinases 
that are activated rapidly in response to many extracel- 
lular signals, that include hormones and growth factors 
whose receptors are protein tyrosine kinases. The acti- 
vation of MAP kinases involves their phosphorylation 
on a threonine and a tyrosine residue (reviewed in [27]), 
both phosphorylations being catalysed by a single MAP 
kinase kinase, that is itself dependent on serine/threon- 
ine phosphorylation for activity [16]. MAP kinases are 
therefore turned on through the activation of a complex 
protein kinase cascade that has yet to be fully eluci- 
dated. MAP kinases transmit he actions of extracellu- 
lar agonists by phosphorylating and activating target 
proteins, that may either be other protein kinases such 
as S6 kinase-If (reviewed in [27]) or MAPKAP kinase 
2 [IS], or transcription factors such as c-jun [28]. The 
preferred consensus equence for phosphorylation by 
MAP kinase is Pro-Xaa-SerIThr-Pro [29,30], although 
the N-terminal proline is not obligatory. 
The highest levels of MAP kinase mRNA and protein 
are found in brain [313. Its normal role and the factors 
that stimulate its activity in this tissue are not well un- 
derstood, although NMDA receptor activation and 
electroconvulsive treatment have been reported to in- 
duce tyrosine phosphorylation of a MAP kinase [32,33]. 
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in this paper we demonstrate that the p42 isoform of 
MAP kinase phosphorylates tau protein in a simiirr 
manner to that observed in Alzheimer’s disease, as 
judged by a large reduction in gel mobility, and the 
phosphorylation of serine-396 and serines- 199 and/or 
-202, two of the sites that are abnormally 
phosphorylated in tau from PHFs [2,83. These results 
are in agreement with a recent study showing that a 
MAP kinase from pig brain phosphorylates tau and 
converts it to an Alzheimer-like state $91. 
Activation of MAP kinase in the absence of an appro- 
priate stimulus is likely to be one of the mechanisms that 
causes cell transformation, since it occurs in response to 
tumour-promoting phorbol esters or when cells are 
transfected with oncogenes such as ras, raf, gip2 and SK 
(reviewed in [34]) which appear to lie upstream of MAP 
kinase kinase in the growth factor-stimulated MAP ki- 
nase cascade. Likewise, the neurofibrillary pathology of 
Alzheimer’s disease could result from the uncoupling of 
a component of the MAP kinase activation cascade 
from regulation by an appropriate xtracellular signal. 
Since brain cells cannot undergo cell division, the conse- 
quence of sustained MAP kinase activation would not 
be uncontrolled celi proliferation. Instead, normal brain 
function might be disrupted by the abnormal phospho- 
rylation of proteins that are not normally phosphor- 
ylated to such an extent in vivo. Abnormal phosphor- 
ylation of proteins, such as tau (which is not phosphor- 
ylated at the T3P and AT8 epitopes in normal adult 
brain [2,8]), might trigger changes in their conformation 
that have a deleterious effect on normal function. 
It is also possible that the abnormal phosphorylation 
Control - 1 h Control 2h 
Fig. 3. Phosphoamino acid analysis of ‘2P-labellcd tau. 3zP-labelled tau 
was incubated in the absence (Control) or presence of PP2A, for 1 11 
or 2 h, which released 40% and 45% of the 3zP-radioactivity, respec- 
tively. The samples were hydrolysed and phosphorylated amino acids 
separated by thin layer electrophoresis, asdescribed [17]. The posi- 
tions oi phosphothrconine (pT), phosphoserinc tpSj, inorganic phos- 
phate (Pi) and the point ofsample application (origin) am markd. The 
other “P-labelled spot represents phosphopeptidcs resulting from in- 
complete hydrolysis. 
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of tau in Alzheimer’s disease does not arise from the 
activation of MAP kinase, but from a decrease in the 
activity of a tau phosphatase. We show here that PP2A 
is the only protein phosphatase with significant activity 
towards “P-labelled tau phosphorylated by MAP ki- 
nase, under our assay conditions. Furthermore, PP%A, 
is easily the most effective species of PP2A in dephos- 
phorylating tau, the free catalytic subunit being almost 
inactive. 
These findings are very similar to those obtained re- 
cently with several physiological substrates of p34cdc2 
([13,35]; P. Ferrigno, T. Langan and P. Cohen, in prep- 
aration). p34cdc2 resembles MAP kinase in phospho- 
rylating serine and threonine residues that are followed 
by a proline residue. However, the preferred consensus 
sequence is (Lys)-Ser/Thr-Pro-Xaa-Lys [36], explaining 
why p34cdc2 is unable to phosphorylate myelin basic 
protein (one of the most effective in vitro substrates for 
MAP kinase) and why MAP kinase cannot phospho- 
rylate histone HI (the standard substrate for p34cdc2). 
A proline immediately C-terminal to the phosphor- 
ylatcd residue has been shown to prevent 
dephosphorylation of small synthetic pcptides by all the 
major types of protein Ser/Thr phosphatase catalytic 
subunits [37,38], presumably explaining why the cata- 
lytic subunit of PP2A depbosphorylates proteins 
phosphorylated by p34cdc2 [35] or MAP kinase so 
poorly. The higher activity of PP2A2 and even higher 
activity of PP’A,, towards both p34cdc2 substrates and 
tau, strongly suggests that the A-subunit in PP2A2 and 
the A and B subunits in PP2A, are able to counteract 
the negative ffect of a C-terminal proline residue. 
This raises the intriguing possibility that a defect in 
one of the B-subunits in brain might underlie the abnor- 
mal phosphorylation of tau which occurs in Alzheimer’s 
disease, since this would be expected to lead to selective 
increases in the phosphorylation of MAP kinase sub- 
strates. 
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